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Abstract Latent Epstein-Barr virus (EBV) infection is causally linked to several human cancers.
EBV expresses viral oncogenes that promote cell growth and inhibit the apoptotic response to
uncontrolled proliferation. The EBV oncoprotein LMP1 constitutively activates NFkB and is critical
for survival of EBV-immortalized B cells. However, during early infection EBV induces rapid B cell
proliferation with low levels of LMP1 and little apoptosis. Therefore, we sought to define the
mechanism of survival in the absence of LMP1/NFkB early after infection. We used BH3 profiling to
query mitochondrial regulation of apoptosis and defined a transition from uninfected B cells (BCL-
2) to early-infected (MCL-1/BCL-2) and immortalized cells (BFL-1). This dynamic change in B cell
survival mechanisms is unique to virus-infected cells and relies on regulation of MCL-1
mitochondrial localization and BFL-1 transcription by the viral EBNA3A protein. This study defines a
new role for EBNA3A in the suppression of apoptosis with implications for EBV lymphomagenesis.
DOI: 10.7554/eLife.22509.001
Introduction
An estimated 15% of cancers worldwide are caused by infectious agents like viruses. Of these,
Epstein-Barr virus (EBV) was the first human tumor virus discovered and is associated with malignan-
cies of both B lymphocyte and epithelial cell origin. Normally, T cells prevent the development of
EBV-associated malignancies and the virus persists quiescently in latently-infected memory B cells.
As a result, nearly all adults in the world are latently infected (Longnecker et al., 2013), making EBV
a particularly widespread and successful pathogen. However, in the absence of a healthy immune
system, such as following organ transplant or HIV infection, EBV can transform B cells leading to
markedly increased rates of lymphoma in these populations.
Primary human B cell infection in vitro by EBV leads to their growth transformation and serves as
a model for oncogenesis in EBV-associated lymphomas. This process requires the expression of six
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viral latent genes: Epstein-Barr Nuclear Antigen 1 (EBNA1), EBNA2, EBNA-LP, EBNA3A, EBNA3C
and Latent Membrane Protein 1 (LMP1) (Longnecker et al., 2013). EBNA2, the major viral transcrip-
tional activator and the first to be expressed upon infection, upregulates expression of the other
viral EBNA genes as well as host genes (Wang et al., 2000; Zimber-Strobl and Strobl, 2001).
EBNA2 also activates the expression of the viral oncoprotein LMP1, which drives the immortalization
of the infected B cell into a lymphoblastoid cell line, or LCL, that proliferates indefinitely in culture.
Together, the EBV latent oncoproteins mimic key aspects of normal B cell biology, promote prolifer-
ation, and inhibit the host innate tumor suppressor response to uncontrolled proliferation (All-
day, 2013; Price and Luftig, 2014).
It is well-established that the LMP1 oncoprotein is necessary for continued LCL growth and sur-
vival (Kaye et al., 1993; Zimber-Strobl et al., 1996). LMP1 mimics a pro-survival TNF receptor that
signals constitutively through the NFkB pathway to promote proliferation and suppress apoptosis in
transformed cells (Cahir-McFarland et al., 2000; Okan et al., 1995; Pratt et al., 2012). In fact, inhi-
bition of the NFkB pathway activated downstream of LMP1 leads to apoptosis in LCLs. However,
recent work from our laboratory has demonstrated that, early after infection, B cells rapidly prolifer-
ate despite low levels of LMP1 expression and NFkB activation (Nikitin et al., 2010; Price et al.,
2012). Surprisingly, these early-infected cells also show no overt signs of apoptosis despite strong
activation of the cellular DNA damage response (Nikitin et al., 2014). This suggests that in early-
infected cells, there is a viral-mediated mechanism independent of LMP1 signaling that promotes
survival.
Several LMP1-independent mechanisms to subvert apoptosis have been described. For example,
the viral BCL-2 homologue BHRF1 confers chemoresistance in a mouse model of Burkitt lymphoma
(BL) (Kvansakul et al., 2010). Similarly, the viral BHRF1 and BALF1 proteins exert non-redundant
roles in protecting initially infected cells from apoptosis (Altmann and Hammerschmidt, 2005). In
addition, expression of the EBNA3 proteins induces resistance to apoptosis in BL cells and primary B
cells by downregulating Bim expression (Paschos et al., 2009; Skalska et al., 2013), thereby making
infected cells less ‘primed’ for apoptosis. The EBNA3 family is also known to epigenetically downre-
gulate additional human genes involved in cell cycle regulation and apoptosis (Allday, 2013; Harth-
Hertle et al., 2013; Hertle et al., 2009; Paschos et al., 2012; Skalska et al., 2013). It has been
shown that the EBNA3 proteins mediate these epigenetic effects, in part, via interacting with
eLife digest Over 90% of adults around the world are infected with the Epstein-Barr virus. Like
other closely related viruses, such as those that cause chicken pox and cold sores, an infection lasts
for the rest of the person’s life, although the virus generally remains in a latent or dormant state.
However, under certain conditions the latent viruses can cause cancers to develop; in fact, it is
estimated that such infections are responsible for nearly 2% of all cancer deaths worldwide.
One way that healthy human cells prevent cancer is by triggering their own death in a process
called apoptosis. The Epstein-Barr virus can block apoptosis, therefore making the cells more likely
to become cancerous. Previous research identified one protein in the Epstein-Barr virus that
promotes cancer by preventing infected cells from dying as normal. However, even in the absence
of this protein, Epstein-Barr virus-infected cells remain resistant to apoptosis. This suggests that the
virus has another way of blocking cell death.
Price et al. have now used a technique that stresses living cells in a way that reveals which
proteins prevent apoptosis to study human cells infected with the Epstein-Barr virus. This revealed
that soon after infection, the virus could force the human cell to produce MCL-1, a protein that
prevents cell death. Later, the Epstein-Barr virus enlisted a second human protein called BFL-1,
which makes the infected cell further resistant to apoptosis.
Price et al. discovered that a protein in the Epstein-Barr virus called EBNA3A controls the
production of the MCL-1 and BFL-1 proteins. In the future, developing therapies that target these
proteins may lead to new treatments for cancers caused by the Epstein-Barr virus. Such treatments
would be likely to have fewer side effects for patients than traditional chemotherapies.
DOI: 10.7554/eLife.22509.002
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additional proteins in such a way that chromatin architecture can be dramatically altered
(Bazot et al., 2015; McClellan et al., 2013). While thought to be generally repressive in nature,
recent work has shown that in some instances EBNA3 proteins can activate gene transcription
(Bazot et al., 2015). In sum, viral proteins confer several survival advantages to infected cells, which
often results in EBV-positive lymphomas that are more difficult to treat than their EBV-negative
counterparts (Kelly et al., 2006).
The intrinsic apoptosis pathway is controlled by complex protein—protein interactions at the sur-
face of mitochondria that regulate the release of cytochrome c (Youle and Strasser, 2008). These
functional interactions can be interrogated with an established approach called ‘BH3 profiling’,
which uses peptides derived from BH3-only pro-apoptotic proteins to identify the anti-apoptotic
BCL-2 family members important for preventing apoptosis in a particular cell (Del Gaizo Moore and
Letai, 2013; Deng et al., 2007). Furthermore, molecular characterization of the interface between
BH3 domains of these proteins has allowed for the creation of a new class of small molecule inhibi-
tors that promote apoptosis directly in sensitive cell types (Billard, 2013; Oltersdorf et al., 2005).
These so-called ‘BH3 mimetics’ are highly specific and show great promise in clinical trials
(Letai, 2008). In this study, we characterized the BH3 profile of uninfected and EBV-infected primary
human B cells from early proliferation through long-term outgrowth. We validated these profiles
using BH3 mimetics and, importantly, identified a novel virus-specific transition in survival mecha-
nisms between early and late stages of latent infection with implications for therapy of EBV-associ-
ated malignancies.
Results
BH3 profiling reveals two distinct stages of mitochondrial priming after
EBV infection
Previously, our laboratory has identified an early period after EBV infection of primary human B cells
where, despite robust virus-mediated proliferation and activation of the pro-apoptotic DNA damage
response, there is little expression of the key viral survival factor LMP1 (Price et al., 2012). In order
to define the mechanism of survival in the absence of LMP1 and NFkB activity early after infection,
as well as through long-term outgrowth, we performed BH3 profiling to query apoptotic priming at
the mitochondria of infected cells. Briefly, this technique works by permeabilizing cells, staining with
a mitochondrial potential-sensitive dye, and then treating cells with peptides derived from the BH3
domains of pro-apoptotic BH3-only proteins, including the activator BH3-only protein BIM and the
sensitizer BH3-only proteins BAD, PUMA, NOXA, BMF, and HRK (Figure 1A). By measuring mito-
chondrial depolarization induced by the activator BH3 peptide, BIM, and the pan-apoptotic sensi-
tizer, PUMA, BH3 profiling can measure the overall ‘priming’ of the cells for apoptosis (that is, the
cell’s distance from the apoptotic threshold). Further, by measuring depolarization induced by the
sensitizer BH3 peptides BAD, NOXA, BMF, and HRK, BH3 profiling can also determine the cell’s spe-
cific dependence on particular anti-apoptotic BCL-2 family proteins, including BCL-2, BCL-XL, MCL-
1, and BFL-1 (Del Gaizo Moore and Letai, 2013). We BH3 profiled three cell states: (i) uninfected B
cells purified from the peripheral blood of normal human donors (B Cell), (ii) FACS-purified prolifer-
ating EBV-infected B cells seven days post-infection (Prolif), and (iii) the resulting EBV-transformed
lymphoblastoid cell lines (LCL) derived five weeks post-infection from the same donors (Figure 1B,
C). Both latently infected cell populations are 100% EBV-positive as shown previously by immuno-
fluorescence and fluorescent in situ hybridization (Nikitin et al., 2010).
BH3 profiling revealed that EBV infection of primary B cells only modestly reduces overall mito-
chondrial priming (Figure 1C, Figure 1—figure supplement 1 compare 10 mM Puma from B to Pro-
lif and 1 mM Bim from B/Prolif to LCL). However, the BH3 profiles revealed marked changes in the
BCL-2 family dependencies between the groups suggesting specific, testable hypotheses
(Figure 1D). For instance, a cell dependent on BCL-2 or BCL-w for survival would exhibit mitochon-
drial depolarization upon exposure to Bad, Puma, or Bmf peptides, while a cell dependent upon
MCL-1 would depolarize upon exposure to Noxa, Puma, or Bmf peptides. Uninfected B cells depo-
larized their mitochondria upon treatment with Bad, Puma, or Bmf peptides, but not Noxa or Hrk
peptides, indicating reliance on BCL-2 or BCL-w as a pro-survival BCL2 family member (Figure 1E).
EBV-infected proliferating B cells (Prolif) lost sensitivity to the Bad peptide but remained sensitive to
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Figure 1. BH3 profiling reveals two distinct stages of mitochondrial priming after EBV infection. (A) Schematic of the BH3 profiling technique, which
involves first permeabilizing the outer membrane followed by incubation with BH3-only peptides to induce depolarization of the mitochondrial
membrane. Depolarization is measured by fluorescent JC-1 dye and quantified. (B) Schematic of EBV-mediated outgrowth of infected CD19+ B cells
into a lymphoblastoid cell line (LCL). Negative isolation of peripheral blood mononuclear cells (PBMCs) yields CD19+ B cells of >95% purity.
Proliferating cells (Prolif) are analyzed by flow cytometry based on the dilution of the fluorescent proliferation tracking dye CellTrace Violet and cells
that have divided more than once are sorted to purity. Monoclonal LCLs are grown out from PBMCs that have been infected with a limiting dilution of
EBV. (C) Analysis of the mitochondrial depolarizations from uninfected B cells, hyper-proliferating infected cells (Prolif), and LCLs when treated with 100
mM of the indicated BH3-only peptides (horizontal axis). Mitochondrial depolarization, normalized to an FCCP control, is reported as the mean value
from five different donors. Error bars indicate standard error of the mean (SEM) from five matched human donors. (bottom, right) Compiled, side-by-
side comparisons of mitochondrial depolarization of the three cell types and more detailed statistical results from paired t-tests are shown below.
*p<0.05, **p<0.01 (D) Schematic of the selective interactions between pro-apoptotic BH3-only and anti-apoptotic BCL2 members. Green boxes and
plus signs indicate protein-binding interactions that lead to mitochondrial depolarization, red boxes indicate no interactions. (E) Schematic of BH3
profiles compiled from uninfected B cells, hyper-proliferating infected cells (Prolif), and LCLs. Shown is the 10 mM Bim treatment, all other treatments
are 100 mM. Numbers and color scale correspond to percentage of mitochondrial depolarization. Formulated hypotheses regarding pro-survival BCL2
members that account for each profile are in the column to the right.
DOI: 10.7554/eLife.22509.003
The following source data and figure supplement are available for figure 1:
Source data 1. Source data for individual responses to BH3 peptides of uninfected, early-infected, and late-infected B cells.
DOI: 10.7554/eLife.22509.004
Source data 2. Source data for individual responses to Bim 1, Puma 10, Bad, and Bmf BH3 peptides of uninfected, early-infected, and late-infected B cells.
DOI: 10.7554/eLife.22509.005
Figure supplement 1. Varying sensitivity to select BH3-only peptides reveals differences in apoptotic regulation during early- and late-infection with
EBV.
DOI: 10.7554/eLife.22509.006
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Puma and Bmf, supporting a survival mechanism reliant on both MCL-1, to block Bad-induced depo-
larization, and BCL-2/BCL-w, to block Noxa-induced depolarization (Figure 1E). Finally, LCLs lost
sensitivity to Bmf, but sensitivity to Puma did not change between Prolif and LCLs, suggesting addi-
tional BFL-1 mediated pro-survival effects in LCLs (Figure 1E).
EBV infection promotes potent resistance to BCL-2 antagonists
We hypothesized that EBV infection reduces the dependence of B cells on BCL-2, BCL-xL, or BCL-w
for survival given the loss of Bad sensitivity between uninfected and early-infected B cells
(Figure 1E). To test this, we treated PBMCs with small molecule BH3 mimetics either concurrent
with EBV infection or at the onset of proliferation (3.5 days post-infection (dpi)) and measured the
number of proliferating EBV-infected B cells at 7 dpi using flow cytometry and the proliferation
tracking dye CellTrace Violet (Figure 2A). We also assayed the sensitivity of monoclonal LCLs to
BH3 mimetic treatment for an equivalent period of time (Figure 2A).
We first tested the sensitivity of EBV-infected cells to ABT-737, a potent small molecule inhibitor
of BCL-2, BCL-xL, and BCL-w (Oltersdorf et al., 2005). Consistent with dependence of uninfected B
cells on these BCL-2 family members predicted by BH3 profiling, treatment with ABT-737 concurrent
Figure 2. EBV Infection promotes potent resistance to BCL-2 antagonists. (A) Schematic of drug treatment time course. (B) Dose-response curves
generated from treating 3–5 human donors with the BCL-2, -xL, and –w inhibitor ABT-737. Percent survival is the percent of proliferating CD19+ B cells
compared to DMSO-treated controls at each time point. (C) Average IC50 with 95% confidence intervals are plotted for ABT-737 treatment at three
different times post infection. (D) Analysis of caspase activity induced by ABT-737. A fluorescent caspase 3/caspase 7 reporter was used and analyzed
by FACS; values are reported as average plus SEM of three human donors. (E) Analysis of phosphatidylserine exposure induced by ABT-737.
Fluorescent Annexin-V was used and analyzed by FACS; values are reported as average plus SEM of three human donors. (F) Same as (B), except the
dose-response is to the BCL-2-specific inhibitor ABT-199. (G) Average IC50 with 95% confidence intervals are plotted of ABT-199 treatment of 2–3
human donors at three different times post infection.
DOI: 10.7554/eLife.22509.007
The following source data is available for figure 2:
Source data 1. Source data for cell counts and apoptosis assays performed with BH3 mimetics targeting BCL-2.
DOI: 10.7554/eLife.22509.008
Price et al. eLife 2017;6:e22509. DOI: 10.7554/eLife.22509 5 of 22
Research article Cancer Biology Microbiology and Infectious Disease
with EBV infection resulted in an IC50 in proliferating B cells of ~10 nM (Figure 2B–C). However,
when ABT-737 was added to EBV-infected cells after the onset of virus-induced proliferation or to
immortalized LCLs we observed high-level ABT-737 resistance with an IC50of ~2–4 mM (Figure 2B–
C). ABT-737 promoted apoptosis as measured by caspase 3/7 activity and Annexin V positivity in
uninfected B cells, while proliferating cells at 7 dpi and EBV transformed LCLs were resistant to apo-
ptosis induction (Figure 2D–E).
We next sought to confirm BCL-2 as the specific anti-apoptotic protein important for uninfected
B cell survival and to further validate our BH3 profiling results. To do this, we used ABT-199, a spe-
cific inhibitor of BCL-2 with minimal off-target effects on BCL-xL or BCL-w (Souers et al., 2013). Sim-
ilar to ABT-737, EBV induced potent resistance to ABT-199 (Figure 2F–G). Therefore, uninfected
human peripheral blood CD19+ B cells depend on BCL-2 for survival and EBV upregulates additional
survival proteins to potently suppress apoptosis induced by BCL-2 antagonism.
MCL-1 and BCL-2 protect EBV-infected proliferating B cells from
apoptosis early after infection, while BFL-1 additionally protects LCLs
from apoptosis late in infection
Our BH3 profiling experiments predicted that EBV-infected B cells are less primed for apoptosis due
to the combined protective effects of MCL-1 and BCL-2 during early proliferation with additional
protection afforded by BFL-1 in immortalized B cells (Figure 1E). To functionally characterize EBV-
regulated survival, we first analyzed BCL-2 family member mRNA expression through B cell out-
growth. We observed that MCL-1 mRNA increased from uninfected B to EBV-infected and proliferat-
ing B cells and was further increased in LCLs (Figure 3A). Over the same infection time course, both
BCL-2 and BFL-1 were initially downregulated in early proliferating B cells relative to uninfected B
cells, then upregulated during LCL outgrowth. These data are consistent with prior transcriptomic
analyses from our group (Price et al., 2012) and others indicating that BCL-2 and BFL-1 are both
ultimately upregulated by EBV (D’Souza et al., 2004; Henderson et al., 1991). BCL-2 and MCL-1
protein levels mirror their respective mRNA expression levels during B cell outgrowth (Figure 3B,
quantified in Figure 3C; note there is no viable BFL-1 antibody). MCL-1 has been known to be
expressed as different isoforms, a long (MCL-1(L)) and a short (MCL-1(S)) (Perciavalle et al., 2012).
While the MCL-1(L) isoform is associated with anti-apoptotic activity, MCL1(S) appears to be more
important for mitochondrial maintenance; thus, for the scope of this study, we focused primarily on
MCL-1(L), referred to as MCL-1. The aforementioned data indicate that ABT-737 resistance coincides
with MCL-1 induction. We therefore sought to test the importance of MCL-1 in promoting EBV-
induced ABT-737 resistance.
We hypothesized that selective inhibition of MCL-1 should render early proliferating cells, but not
LCLs, sensitive to drugs that target BCL-2, namely ABT-737 and the BCL-2 specific inhibitor ABT-
199. Treatment of EBV-infected proliferating B cells at 7dpi or LCLs with either ABT-737, ABT-199,
or a specific MCL-1 inhibitor A1210477 (A-1210) induced minimal apoptosis (Figure 3D–E). How-
ever, when cells were treated with both A-1210 and either ABT-737 or ABT-199, early proliferating
cells, but not LCLs, displayed elevated markers of apoptosis (Figure 3D–E). The combined action of
ABT-199 and A-1210 supports the hypothesis generated by BH3 profiling that early-infected cells
are more dependent upon MCL-1 and BCL-2 for survival than are LCLs.
Further corroborating these findings, we found that indirect inhibition of MCL-1 with flavopiridol
led to sensitivity of early-infected cells to BCL-2 antagonists. MCL-1 is a highly labile transcript and
protein, and its expression is known to be sensitive to RNA polymerase II stalling induced by CDK9
inhibition (Gojo et al., 2002). Indeed, the CDK9 inhibitor, flavopiridol, induced rapid decreases in
MCL-1 mRNA and protein, while leaving BCL-2 and BFL-1 levels largely unaffected (Figure 3—figure
supplement 1A–B). Supporting our A-1210 data, we found that early proliferating cells were more
sensitive to apoptosis induced by a combination of flavopirodol and ABT-737 than LCLs (Figure 3—
figure supplement 1C) (Leverson et al., 2015).
To determine if BFL-1 was important for survival in LCLs, we utilized the CRISPR/Cas9 system to
induce mutations in the BFL1 (Bcl2a1) coding sequence. We successfully generated a clonal LCL with
deletions in both BFL1 alleles as assessed by Sanger sequencing (Figure 3F). In one allele there is a
24 base pair (bp) in-frame deletion removing a critical loop prior to the BH3 binding cleft and the
other a 29 bp deletion in the BFL1 gene resulting in a frameshift mutation and a subsequent prema-
ture stop codon at amino acid 50 of the BFL-1 protein. These deletions were clearly evident by RT-
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Figure 3. MCL-1 collaborates with BCL-2 to protect EBV-infected proliferating B cells early after infection while BFL-1 additionally protects LCLs late
after infection. (A) Quantitative PCR (qPCR) of MCL-1, BCL-2, and BFL-1 mRNA levels post EBV infection. Average plus SEM of three human donors is
plotted. (B) Immunoblot analysis of MCL-1 isoforms, BCL-2, EBNA2, LMP1, and Magoh (loading control) during B cell immortalization. Protein lysates
from three matched donors were obtained from uninfected B cells and infected B cells sorted Day seven post-infection for proliferating cells (Prolif).
Three unmatched LCLs were also included. (C) Protein levels of MCL-1(L) and BCL-2 from (B) were quantified by densitometry and normalized to the
Magoh loading control. Average relative protein abundance is reported plus SEM of three donors. (D) Analysis of apoptosis by Annexin-V positivity in
Day seven proliferating EBV-infected cells and LCLs that were treated with A1210477 (A-1210) with or without concurrent ABT-737 for 24 hr.
Figure 3 continued on next page
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PCR (Figure 3F), and, consequently, the mutant DBFL-1 LCL expressed significantly reduced levels
of BFL-1 mRNA as compared to WT LCL, LCL expressing Cas9 alone or Cas9-expressing LCLs tar-
geting AAVS1 as a negative control (Figure 3G). DBFL-1 LCLs were significantly more sensitive to
treatment with a combination of ABT-737 and A-1210 relative to WT, Cas9, or AAVS1 sgRNA control
LCLs (Figure 3H). These data support the hypothesis defined by our BH3 profiling data that LCLs
depend on BFL-1, MCL-1, and BCL-2 to protect from apoptosis induced by viral oncoprotein-driven
proliferation.
Resistance to BCL-2 antagonism is virus specific
A hallmark of B cell biology is rapid proliferation in response to antigen and cytokines leading to
maturation via germinal center reactions into the memory and plasma cell lineages (Goodnow et al.,
2010). In cell culture, mitogens such as the TLR9 ligand CpG DNA as well as T cell derived CD40
ligand and IL-4 (CD40L/IL-4) promote B cell proliferation similar to EBV infection (Elgueta et al.,
2009; Krieg et al., 1995; Nikitin et al., 2014) (Figure 4A–C). To assess whether EBV-mediated
ABT-737 resistance was linked to B cell proliferation per se or was specific to EBV infection, we stim-
ulated primary B cells with CpG or CD40L/IL-4 and queried survival. We found that, while EBV
induced marked ABT-737 resistance (IC50 ~3–4 mM), both CpG and CD40L/IL-4 stimulated B cells
were significantly more sensitive to ABT-737 (IC50 ~200 nM) (Figure 4D–E). Consistently, mitogen-
stimulated proliferating B cells had increased caspase 3/7 activity and Annexin V positivity following
ABT-737 treatment (Figure 4F–G) while EBV-infected cells displayed only marginally increased activ-
ity above basal levels (Figure 2D–E). These data strongly support the hypothesis that resistance to
BCL-2 antagonism is specific to EBV-induced proliferation. We next sought to characterize the EBV
factors necessary for ABT-737 resistance.
EBV-induced resistance to BCL-2 antagonism is mediated by EBNA3A
EBV requires expression of protein products from the heavily spliced Epstein-Barr Nuclear Antigen
(EBNA) transcriptional unit to promote B cell proliferation and survival (Price and Luftig, 2014). Of
key importance is EBNA2, a protein encoded initially by transcripts from the B cell-specific viral W
promoter (Wp). EBNA2 subsequently activates the viral C promoter (Cp) just upstream of Wp which
drives increased expression of EBNA2 as well as the other EBNAs (Price and Luftig, 2014;
Woisetschlaeger et al., 1991) (Figure 5A). To assess the role of EBNA2 in ABT-737 resistance of
early-infected cells, we used an EBNA2-deleted strain of EBV called P3HR1 (Hinuma et al., 1967).
Since the EBNA2 deletion in P3HR1 renders the virus incapable of inducing proliferation and
Figure 3 continued
Measurements were taken as a percentage of the proliferating B cell population and plotted as average plus SEM of three human donors. Data were
analyzed by 2-way ANOVA, which showed a significant interaction between cell type and drug treatment (p=0.0352). *p=0.0146, by two-tailed Student’s
t-test. (E) Same as (D) but with ABT-199 for 24 hr. Measurements were taken as a percentage of the proliferating B cell population and plotted as
average plus SEM of three human donors. Data were analyzed by 2-way ANOVA. No significant interaction between cell type and drug treatment
(p=0.6288). (F) (Left) Agarose gel of RT-PCR products from DBFL-1 mutant cell line generated with the CRISPR/Cas9 system. Controls included are from
a matched LCL wildtype (WT), Cas9-only expressing (Cas9) LCL, and Cas9-expressing LCL that was transduced with an sgRNA specific to the adeno-
associated virus integration site (AAVS1) on the human genome (DAAV). Ladder (L) on the left is included. (Right) The sequences for the wildtype and
mutant BFL1 sequences with the BFL1-specific sgRNA (in blue), PAM site (in red), and allele-specific SNP (in green). (G) qPCR of BFL-1 mRNA levels in
WT, Cas9, DAAV, and DBFL-1 cell lines. Average plus SEM of three independent experiments are plotted. (H) Analysis of apoptosis by Annexin-V
positivity in WT, Cas9, DAAV, and DBFL-1 cell lines that were treated with A-1210 with or without concurrent ABT-737 treatment. Measurements were
taken as a percentage of the proliferating B cell population and plotted as average plus SEM of three independent experiments. Data were analyzed
by 2-way ANOVA, which showed a significant interaction between cell type and drug treatment (p=0.0004). ***p=0.0002, by two-tailed Student’s t-test.
DOI: 10.7554/eLife.22509.009
The following source data and figure supplement are available for figure 3:
Source data 1. Source data for protein and mRNA expression levels of anti-apoptotic members, apoptotic assays, and characterization of a BFL1-
CRISPR mutant.
DOI: 10.7554/eLife.22509.010
Source data 2. Source data for Figure 3—figure supplement 1.
DOI: 10.7554/eLife.22509.011
Figure supplement 1. Flavopiridol sensitizes EBV-infected early-proliferating B cells to ABT-737.
DOI: 10.7554/eLife.22509.012
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transforming primary B cells (Miller et al., 1974), we compared the ABT-737 sensitivity of P3HR1-
infected cells induced to proliferate using the TLR9 ligand CpG (P3HR1+CpG) to uninfected B cells
treated with CpG. P3HR1 infection did not alter the sensitivity of CpG-treated proliferating B cells to
ABT-737 (Figure 5B). In contrast, the prototypical transforming strain, B95-8, induced marked ABT-
737 resistance in the presence or absence of CpG (Figure 5B). These data implicate EBNA2 as a key
determinant of the ABT-737 resistance phenotype.
Since EBNA2 controls the expression of other EBV latency genes, it was important to assess the
expression of these genes during early P3HR1 and B95-8 infection. At 2 days post-infection, a time
point at which ABT-737 resistance first emerges (Figure 5—figure supplement 1), P3HR1-infected
Figure 4. Resistance to BCL-2 antagonism is virus specific. (A) Flow cytometry plot of proliferating (Prolif) EBV-infected PBMCs. (B) Same as in (A), but
treated with the TLR9-ligand CpG DNA. (C) Same as in (A), but treated with soluble recombinant CD40L and IL-4. (D) Dose-response curves generated
from treating EBV-infected or mitogen-stimulated proliferating B cells with ABT-737 on Day 3.5 post infection/stimulation and reading percent survival
on Day seven post infection/stimulation. Percent survival is the percent of proliferating CD19+ B cells compared to DMSO-treated controls at each time
point. Data are from three human donors. (E) Average IC50 with 95% Confidence Intervals are plotted for ABT-737 treatment on EBV-infected or
mitogen-stimulated cells. (F) Caspase 3/7 activity in proliferating CpG and CD40L/IL-4 stimulated cells increases with increasing concentrations of ABT-
737; values are reported as average plus SEM of three human donors. Two-tailed t-test results: CpG, DMSO vs 1000 nM (*p=0.0157); CD40L/IL-4,
DMSO vs 1000 nM (**p=0.0046). (G) Annexin V positivity in proliferating CpG and CD40L/IL-4 stimulated cells increases with increasing concentrations
of ABT-737; values are reported as average plus SEM of three human donors. Two-tailed t-test results: CpG, DMSO vs 1000 nM (**p=0.0042); CD40L/IL-
4, DMSO vs 1000 nM (**p=0.0002).
DOI: 10.7554/eLife.22509.013
The following source data is available for figure 4:
Source data 1. Source data for cell counts and apoptotic assays of uninfected, mitogen-stimulated B cells.
DOI: 10.7554/eLife.22509.014
Price et al. eLife 2017;6:e22509. DOI: 10.7554/eLife.22509 9 of 22
Research article Cancer Biology Microbiology and Infectious Disease
cells express high levels of Wp-driven transcripts, but significantly less Cp-driven transcripts includ-
ing EBNA2, EBNA3A, and EBNA3C relative to B95-8 infected cells (Figure 5C). As recent work indi-
cates that the viral BCL-2 homologue, BHRF1, is expressed from Wp during primary B cell infection
(Kelly et al., 2009) and over-expression of BHRF1 can prevent apoptosis induced by ABT-737 in
mouse cells (Kvansakul et al., 2010), it was important to analyze BHRF1 expression. We found that
P3HR1-infected cells expressed similar levels of BHRF1 as B95-8 infected cells (Figure 5C). There-
fore, BHRF1 was not associated with ABT-737 resistance in early-infected B cells.
Resistance to ABT-737 could be conferred by EBNA2 or by a downstream target such as the
EBNA3 proteins. While EBNA3A and EBNA3C are both important for B cell transformation,
EBNA3A- and EBNA3C-deleted viruses can induce B cell proliferation for several weeks in culture
Figure 5. EBV-induced resistance to BCL-2 antagonism is mediated by EBNA3A. (A) Schematic to show the genetic differences between prototypical
transforming strain of EBV (B95-8) and P3HR1 (EBNA2-deleted) strain. (B) Dose-response curves to assess ABT-737 sensitivity in proliferating
prototypical (B95-8) EBV-infected cells and EBNA2-deleted (P3HR1) EBV-infected cells. To induce proliferation, P3HR1-infected cells required additional
co-treatment with CpG DNA. Data are from three human donors. Average IC50 is shown (inset). (C) qPCR showing early viral mRNAs expressed at day
two post infection normalized to a B95-8 LCL. Data are shown as SEM of two matched human donors. While P3HR1 produces the same relative amount
of Wp-driven transcripts and BHRF1, P3HR1 does not induce C promoter (Cp)-driven transcripts or the viral EBNA2,  3A, and  3C transcripts. (D) Early-
infected proliferating EBNA3A-deleted (4EBNA3A) EBV-infected cells are sensitive to ABT-737, while EBNA3C-deleted (4EBNA3C) EBV-infected cells
and wildtype-infected proliferating cells maintain high levels of ABT-737 resistance. Percent survival is the percent of proliferating CD19+ B cells
compared to DMSO-treated controls at each time point. Data shown are from 3 to 6 human donors with SEM. Average IC50 is shown (inset). (E)
EBNA3A-deleted LCLs (43A LCL) are more sensitive to ABT-737 than wildtype LCLs. Data are from three biological replicates with SEM. Average IC50
is shown (inset).
DOI: 10.7554/eLife.22509.015
The following source data and figure supplement are available for figure 5:
Source data 1. Source data for cell counts performed with cells infected with EBV mutant strains and mRNA levels of EBV viral transcripts.
DOI: 10.7554/eLife.22509.016
Source data 2. Source data for Figure 5—figure supplement 1.
DOI: 10.7554/eLife.22509.017
Figure supplement 1. ABT-737 resistance is gained within two days post infection.
DOI: 10.7554/eLife.22509.018
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before aborting long-term outgrowth (Anderton et al., 2008; Skalska et al., 2013). To explore the
potential role of the EBNA3 proteins in mediating ABT-737 resistance, we infected PBMCs with
mutant strains of EBV deleted for EBNA3A or EBNA3C (43A, 43C), and treated them with ABT-737
at 3.5 dpi then assayed for survival at 7 dpi as before. While 43C-infected proliferating B cells were
resistant to ABT-737 (IC50 ~3 mM) similar to WT B95-8-infected cells (IC50 ~4 mM), the 43A-infected
proliferating B cells remained highly sensitive to ABT-737 (~200 nM) (Figure 5D). Furthermore, from
our initial infections we were able to derive a 43A LCL, similar to that reported by others
(Hertle et al., 2009; Skalska et al., 2010), and we again observed enhanced sensitivity to ABT-737
and ABT-199 in the 43A LCL (IC50 ~60 nM and ~180 nM, respectively) relative to a donor-matched
WT LCL (IC50 ~4 mM) (Figure 5E, Figure 5—figure supplement 1C). This result was unexpected as
LMP1-mediated NFkB activity in a 43A LCL should induce BFL-1 to rescue ABT-737 resistance
(D’Souza et al., 2004; Pratt et al., 2012) (Figure 1E).
EBNA3A is required for MCL-1 mitochondrial localization and BFL-1
transcription
To further characterize the nature of EBNA3A-mediated ABT-737 resistance, we subjected 43A and
WT LCLs from the same donor to BH3 profiling. We found that the 43A LCL, in contrast to WT, was
sensitive to both the Bad and Bmf peptides indicating BCL-2 dependence and an absence of BFL-1
and MCL-1 protection similar to the uninfected B cell state (Figure 6A). Mechanistically, we found
that 43A LCLs expressed significantly less BFL-1 at the mRNA level, while the BCL-2 and MCL-1
mRNA levels were similar to WT, if not slightly elevated (Figure 6B and additional clones in Fig-
ure 6—figure supplement 1A). Loss of BFL-1 mRNA expression was not due to selective pressure
applied during outgrowth of 43A LCL as EBNA3A-ERT2 fusion protein expressing LCLs lost or
gained BFL-1 expression upon HT withdrawal or addition, respectively, in a stable LCL (Figure 6—
figure supplement 1B–C). While BH3-profiling predicted a loss of MCL-1 activity, MCL-1 mRNA,
protein, and protein stability were unchanged in the 43A LCL compared to WT (Figure 6B–D).
Instead, we discovered that MCL-1 localization to mitochondria was defective in the 43A LCL
(Figure 6E). These data strongly corroborate the BH3 profiling results, which indicated a lost of
MCL-1 acitivity at the mitochondria.
We further sought to determine how EBNA3A regulates BFL-1 and specifically to characterize
whether the loss of BFL-1 mRNA in the 43A LCL was due to a transcriptional defect (Figure 6B).
Indeed, when we isolated nascent mRNAs using a thiolated-RNA pull down method we found that
43A LCLs were only transcribing ~15% as much BFL-1 mRNA as WT LCLs (Figure 6F). Furthermore,
we found that decreased BFL-1 transcription in 43A LCLs was correlated with decreased RNA poly-
merase II (Pol II), activated Pol II (phospho Serine 5), and activating histone marks (H3K27ac,
H3K9ac, and H3K4me3) accumulating at the BFL-1 transcription start site (TSS) (Figure 6G).
EBNA3 proteins often regulate gene expression through long-range enhancers (Bazot et al.,
2015; McClellan et al., 2013; Schmidt et al., 2015). To evaluate the role of EBNA3A in regulating
chromatin structure to promote BFL-1 transcription, we used chromatin conformation capture to
query the interactions between regions of open chromatin up- and downstream of the BFL-1 gene in
WT and 43A LCLs. We discovered two genomic regions upstream of the BFL-1 gene that were
strongly associated with the TSS in WT LCLs but less so in 43A LCLs (Figure 6H). Using LCL ChIP-
Seq data (Schmidt et al., 2015; Zhao et al., 2011), we found that one locus is bound by EBNA3A
within a known EBV Super Enhancer (39 kb upstream of the BFL-1 TSS) and the other region contains
a single RelA peak, an NFkB transcription factor subunit strongly activated by LMP1 (Zhao et al.,
2014) (Figure 6I). These data support an important new role for EBNA3A in coordinating NFkB-
mediated regulation of BFL-1 transcription in LCLs.
Finally, to demonstrate that EBNA3A is responsible for ABT-737 resistance in EBV-infected B
cells, we rescued EBNA3A expression in trans in 43A LCLs. We found that EBNA3A re-expression
was sufficient to restore ABT-737 resistance similar to WT LCLs (Figure 6J–K). Therefore, we con-
clude that EBNA3A plays an important role in EBV-mediated resistance to BCL-2 antagonists and
survival in response to potent proliferative signals during both early and late stages of B cell growth
transformation.
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Figure 6. EBV EBNA3A is required for MCL-1 mitochondrial localization and BFL-1 transcription. (A) BH3 profile shows increased sensitivity to Bad and
Bmf peptides in EBNA3A-deleted LCLs compared to wildtype LCLs, indicative of a BCL-2 dependence. Three technical replicates with seven repeated
measures each over time were averaged and plotted with SEM. Data were analyzed by paired 2-tailed t-test, *p<0.001. (B) qPCR of BCL-2, MCL-1, and
BFL-1 mRNA levels in matched wild type and EBNA3A-deleted LCLs from four human donors. NS, not significant, ***p=0.002 (C) Western blot of MCL-
Figure 6 continued on next page
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Discussion
Suppression of apoptosis by EBV is essential for establishment of latent infection in the immune-
competent host and promotes tumorigenesis in the immune suppressed host. While EBV encodes
two putative BCL-2 homologues, these proteins are not required for survival after the first 24 hr fol-
lowing B cell infection (Altmann and Hammerschmidt, 2005). Rather, constitutive NFkB signaling
from the viral oncoprotein LMP1, a TNFR homologue, is thought to be responsible for apoptotic
suppression in latently infected, proliferating cells (Cahir-McFarland et al., 2000; Pratt et al.,
2012). However, the initial burst of B cell proliferation induced by EBV is driven by expression of the
viral EBNA transcription factors (EBNA1, 2, 3A, 3B, 3C, and LP) in the absence of appreciable LMP1
or NFkB activity (Price et al., 2012). Furthermore, this early period of hyper-proliferation activates a
growth-suppressive DNA damage response, which would be expected to promote apoptosis
(Nikitin et al., 2010). We, therefore, sought to identify the mechanism of survival during early infec-
tion by using BH3 profiling to query mitochondrial control of apoptosis prior to and through latent
EBV infection and outgrowth of primary human B cells into LCLs. While BH3 profiling has been previ-
ously performed on virus-infected cells (Cojohari et al., 2015), this study focused on HCMV and was
limited to a single EBV-positive Burkitt lymphoma cell line, Akata, which expresses only the viral
EBNA1 protein. In our BH3 profiling study, we found that mature human peripheral blood B cells
depend solely on BCL-2 for survival while EBV latent infection further suppressed apoptotic priming
during outgrowth by initially upregulating MCL-1, followed by BFL-1. Mechanistically, we identified a
new and unique role for the viral latent protein EBNA3A in apoptosis resistance during both early
and late EBV-induced B cell proliferation.
The importance of EBNA3A in B cell transformation and survival was previously recognized, but
our studies now define the molecular basis for the inhibition of apoptosis. While both EBNA3A and
EBNA3C suppress the pro-apoptotic protein Bim (Paschos et al., 2009), only EBNA3A was required
to mitigate resistance to a BCL2 antagonist through outgrowth. EBNA3A regulated the BH3 profile
of EBV-infected cells and suppressed apoptosis by promoting MCL-1 mitochondrial localization and
increasing BFL-1 mRNA transcription. Transcription of BFL-1 was previously shown to be regulated
by the EBV transcription factor EBNA2 (Pegman et al., 2006) as well as LMP1-induced NFkB
(Pratt et al., 2012). Our work now indicates that EBNA3A coordinates a chromatin architecture
through an EBV super enhancer that facilitates NFkB-mediated activation of BFL-1 transcription.
Figure 6 continued
1 in WT or 43A LCLs treated with 15 mM cycloheximide (CHX) over two hours. (D) The relative mean densitometry from panel (C) plotted over time
from two biological replicates plus SEM. (E) Sub-cellular fractionation into total (T), cytoplasmic (C), or mcitochondrial (M) compartments reveals MCL-1
mislocalization in an EBNA3A-deleted LCL compared to a Wildtype LCL. Immunoblot for MCL-1, VDAC (mitochondrial localization control), and b-Actin
(total lysate control). Quantified levels of MCL-1 in total and mitochondrial compartments are normalized to their respective WT levels and VDAC
control. (F) Relative transcription rate of BFL-1 in WT and 43A LCLs ascertained by qPCR on pulldown of nascent mRNAs. Data is shown as the average
and SEM of three biological replicates. (G) Chromatin immunoprecipitation (ChIP) was performed on extracts from WT and 43A LCLs using antibodies
for total RNA Pol II (Pol II), Pol II phospho-Ser 5 (Pol II Ser 5), H3K27ac, H3K9ac, and H3K4me3. Primer pairs for Myo were used as a negative control,
CXCL10 as an EBNA3A-repressed control, and miR221/222 as an EBNA3A-activated control. Primer pairs surrounding the BFL-1 TSS are shown
annotated in panel (I) in their proper locations. Values represent ratio of chromatin precipitated, after correction for IgG, relative to 2.5% of input. Data
are shown as the mean and standard deviation (SD). (H) Chromatin conformation capture (CCC) was performed on WT and 43A LCLs, and the BFL-1
loci were interrogated for interaction after digesting with HindIII. Relative interaction frequency to the BFL-1 TSS fragment (panel I bottom) was assayed
by qPCR and normalized to the interaction frequency of the nearest neighbor ( 1) fragment set at 100% relative interaction. Results are the average of
two independent experiments. (I) ChIP-Seq data for EBNA2, EBNA3A, EBNA3C, NFkB (RelA), Histone H3K27ac, p300, and RNA Pol II (Pol II) from an
LCL on the BCL2A1 (BFL-1) locus. (J) EBNA3A protein expression can be rescued to wild-type LCL levels in a 43A LCL using an episomal EBNA3A
expression vector. (K) Rescuing EBNA3A expression in 43A LCLs restores resistance to ABT-737. Three individual clones of WT, 43A, or 43A/EBNA3A
were subjected to ABT-737 treatment for three days and then analyzed for viability by FACS. Remaining viable cells on day three post treatment are
normalized to the untreated (0 nM) cells. Data were analyzed by 2-way ANOVA and showed that there was a significant interaction (p<0.001) between
cell type and drug treatment. NS, not significant; **p=0.01 by two-tailed t-test.
DOI: 10.7554/eLife.22509.019
The following source data and figure supplement are available for figure 6:
Source data 1. Source data for individual responses to BH3 peptides, mRNA and protein levels.
DOI: 10.7554/eLife.22509.020
Figure supplement 1. Additional validation of BFL-1 mRNA regulation by EBNA3A.
DOI: 10.7554/eLife.22509.021
Price et al. eLife 2017;6:e22509. DOI: 10.7554/eLife.22509 13 of 22
Research article Cancer Biology Microbiology and Infectious Disease
Therefore, our studies highlight a new cooperative role among EBNA3A, EBNA2, and LMP1 in tran-
scriptional activation important for EBV-immortalized cell survival.
The importance of MCL-1 in early EBV-infected human B cells coupled with the critical role of
MCL-1 in germinal center (GC) formation and memory B cell survival in the mouse (Vikstrom et al.,
2010) is consistent with the GC model of EBV infection. The GC model posits that EBV infection of
naı¨ve B cells promotes B cell maturation mimicking the GC reaction to access the long-lived memory
B cell compartment and thus persisting for the lifetime of the host (Burns et al., 2015; Roughan and
Thorley-Lawson, 2009). Our data support this model in that early infection of B cells by EBV pro-
motes MCL-1 as a critical apoptotic regulator similar that observed for GC B cells in the mouse
(Vikstrom et al., 2010). Furthermore, MCL-1 copy number gains and mutations are often found in B
cell lymphomas (Wenzel et al., 2013). Therefore, the mechanism by which EBNA3A enhances MCL-
1 function at the mitochondria may provide broad insight into apoptotic regulation during B-cell
maturation and lymphomagenesis.
The early phase of EBV infection where EBNAs are expressed with little or no expression of LMPs
is known as latency IIb (Price and Luftig, 2015). The latency IIb expression pattern has also been
observed by immuno-histochemical analysis in EBV-positive HIV-associated lymphomas, post-trans-
plant lymphomas, in acute infectious mononucleosis, and in tumors of humanized mouse models of
EBV infection (Price and Luftig, 2015). Indeed, a recent study found that an EBV recombinant lack-
ing LMP1 was capable of forming B cell tumors in a humanized mouse model (Ma et al., 2015). The
survival of these cells as well as those in other latency IIb expressing tissues likely depends on
EBNA3A and MCL-1, while latency III cells expressing LMP proteins and high level NFkB signaling
are likely to be less primed and to rely on BFL-1. As BH3 profiling has been a powerful predictive
tool for chemotherapeutic responses in leukemias (Montero et al., 2015), our new findings suggest
that such an approach could allow for better treatment decisions for EBV-associated malignancies.
Materials and methods
Cells, viruses, and mitogens
Buffy coats were obtained from normal human donors through the Gulf Coast Regional Blood Cen-
ter (Houston, TX) and peripheral blood mononuclear cells (PBMCs) were isolated by Ficoll Histopa-
que-1077 gradient (Sigma, H8889). CD19+ B cells were purified from PBMCs using the BD iMag
Negative Isolation Kit (BD, 558007). Lymphoblastoid cell lines were generated as previously
described (Price et al., 2012) and maintained in RPMI plus 10% FBS (Corning), 2 mM L-Glutamine,
100 U/ml penicillin, 100 mg/ml streptomycin (Invitrogen).
B95-8 strain of Epstein-Barr virus was produced from the B95-8 Z-HT cell line as previously
described (Johannsen et al., 2004). P3HR1 was generated from P3HR1 Z-HT cells (kind gift of Elliott
Kieff, Harvard Medical School). Two independent sources of EBNA3A and EBNA3C deletion viruses
were used in these studies for validation as well as an EBNA3A-ERT2 regulated recombinant
(Bazot et al., 2015). Detailed information on mutant viruses below.
TLR9 ligand CpG oligonucleotide (ODN 2006) was purchased from IDT and used at 2.5 mg/ml
(Krieg et al., 1995). Human recombinant interleukin-4 (PeproTech, AF200-04) was used at 20 ng/
mL. HA-tagged CD40 ligand was purchased from (R&D Systems, 6420 CL) and used at 5 ng/ml in
combination with an anti-HA cross-linking peptide (R&D Systems, MAB060; RRID:AB_10719128) at a
concentration of 0.2 mg/ml.
Initial BH3 profiling experiments were performed with cell populations and lines that were not
mycoplasma tested. However, subsequently we instituted routine mycoplasmia testing using a PCR-
detection kit (Sigma-Aldrich, MP0035-1KT). While the majority of cell lines were negative for myco-
plasma, we did detect mycoplasma in some lines. These lines were cured with ciprofloxacin treat-
ment. We repeated several key experiments in those lines that were found to be positive and then
cured, including ABT-737 and ABT-199 sensitivity assays, and found that mycoplasma contamination
had no bearing on the results.
Virus strain generation and production
Two independent sources of EBNA3A and EBNA3C deletion viruses were used in these studies for
validation. One set was previously described (Anderton et al., 2008). The other was generated by
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en passant mutagenesis of the EBV p2089 BACmid (Delecluse et al., 1998) using GS1783 E. coli
(Braman, 2010). Primer sequences used to generate these mutants are listed in Supplementary file
1. After screening, desired EBV BACmids were transferred to BM2710 E. coli which were then used
to infect 293 cells as previously described (Chen et al., 2005).
Recombinant viruses were produced by co-transfecting BAC-containing, selected 293 cells with
pCDNA3-2670-gp110, pSG5-Zta, and pCDNA3-Rta into cells using polyethylenimine (PEI) and Opti-
MEM (Invitrogen). 24 hr after transfection, media was changed to antibiotic-free 10% FBS containing
RPMI 1640 and harvested 48 hr afterwards. After harvesting, transfected cells were replenished with
fresh media for 24 hr, at which point virus was harvested again. Harvests were pooled and concen-
trated 100-fold in a 100 kDa Amicon spin-filter.In addition to the EBNA3A deletion and stop var-
iants, a recombinant virus was used that encodes EBNA3A-ERT2, which is a fusion of a modified
estrogen receptor to EBNA3A. This virus was previously used to define EBNA3A regulated genes
and its generation was described here (Bazot et al., 2015).
Virus infections
EBV infections were performed by adding 100 mL B95-8 virus (from Z-HT supernatants) or 200 mL
P3HR1 virus to 1  106 PBMCs for 1 hr at 37˚C in a CO2 incubator followed by washing the cells
once with PBS and resuspending cells in RPMI with 15% FBS serum (Corning), 2 mM L-Glutamine,
100 U/ml penicillin, 100 mg/ml streptomycin (Invitrogen), and 0.5 mg/mL Cyclosporine A (Sigma).
Cells were cultured at 37˚C in a humidified incubator at 5% CO2 (Nikitin et al., 2010). For P3HR1
infections, viral stocks were normalized to B95-8 by immunofluorescence of EBNA-LP in primary B
cells two days post infection. For WT, 43A, and 43C BAC viruses, 1  105 green Raji units (GRU;
Raji, RRID:CVCL_2699) were used to infect 1  106 PBMCs as previously described (Skalska et al.,
2013).
Generation of CRISPR/Cas9 mutants
The BFL-1 CRISPR/Cas9 mutant LCL was generated by the Duke Functional Genomics Shared
Resource. Cas9-expressing LCLs (lentiCas9-EGFP; Addgene #63592) were transduced with one of
three short-guide RNAs (sgRNAs) that were specific to BFL-1 exon 1 and grown out under puromy-
cin selection (lentiGuide-Puro; Addgene #52963). Each sgRNA was screened for efficiency of Cas9
cleavage by Surveyor nuclease assay and for reduced BFL-1 mRNA expression. LCLs transduced with
the sgRNA resulting in both Cas9 cleavage of the target site and the most reduced mRNA expres-
sion were then serially diluted to obtain a clonal population. Clonality was ascertained by TOPO TA
cloning (Invitrogen, Cat #45003).
Flow cytometry and sorting
To track proliferation, cells were stained with CellTrace Violet (Invitrogen, C34557). Cells were first
washed in FACS buffer (5% FBS in PBS), stained with the appropriate antibody for 30 min-1hr at 4˚C
in the dark, and then washed again before being analyzed on a BD FACS Canto II.
Proliferating infected B cells were sorted to a pure population of CD19+/CellTraceVioletlo on a
MoFlo Astrios Cell Sorter at the Duke Cancer Institute Flow Cytometry Shared Resource. Mouse
anti-human CD19 antibody (clone 33-6-6; gift from Tom Tedder, Duke University Medical School)
conjugated with either APC or PE was used as a surface B-cell marker in flow cytometry.
BH3 profiling (JC-1 plate-based assay)
Plate-based BH3 profiling was performed on primary B cells, early-infected hyperproliferating B cells,
and LCLs at 5  104 cells/well. Cells were resuspended at 2x and incubated for 10 min at room tem-
perature (RT) in T-EB solution containing 4 mM JC-1, 40 ug/mL oligomycin, 0.02% digitonin, and 20
mM 2-mercaptoethonal. Peptides were diluted in T-EB at 2x concentration and aliquoted per well in
a black 384-well plate (Corning 3575), to which the cell/dye solution was added 1:1. The fluores-
cence at 590 nM from each well was read on a plate reader every 5 min at RT. Depolarization of the
mitochondria was calculated as a percentage loss normalized to the solvent-only control (DMSO, 0%
depolarization) and the positive control (FCCP, 100% depolarization). Analysis was performed using
technical triplicates of five biological replicates, where outliers were eliminated if there was poor sig-
nal or if the Puma2A inert control showed high background depolarization.
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Protein expression
Cells were pelleted and washed in PBS, and then lysed in 0.1% Triton-containing buffer with Com-
plete protease inhibitors. All protein lysates were run on NuPage 4–12% gradient gels (LifeTechnol-
ogy) and transferred to PVDF membrane (GE Healthcare). Membranes were blocked in 5% milk in
TBST and stained with primary antibody overnight at +4˚C, followed by a wash and staining with sec-
ondary HRP-conjugated antibody for 1 hr at room temperature. All antibodies used can be found in
the Supplementary file 1.
Gene expression analysis
Total RNA was isolated from cells by using a Qiagen RNeasy kit and then reverse transcribed to gen-
erate cDNA with the High Capacity cDNA kit (Applied Biosystems). Quantitative PCR was performed
by using SYBR green (Quanta Biosciences) in an Applied Biosystems Step One Plus instrument.
Results were normalized to SETDB1, a control mRNA found to not change expression from resting B
cells through EBV-immortalization (Price et al., 2012) or GNB2LI (Bazot et al., 2015).
Small molecule inhibitors
Cells were treated with various concentrations of ABT-199 (ChemieTek, CT-A199), ABT-737 (Selleck-
chem, S1002), flavopiridol (Sigma, F3055), or A1210477 (Selleckchem, S7790). All drugs were resus-
pended in DMSO.
Cell viability assays
Cells were stained with fluorescent conjugates of Annexin-V (eBioscience, 88-8007-72; RRID:AB_
2575165) or incubated with CellEvent Caspase 3/7 Green Detection Reagent (ThermoFisher Scien-
tific, C10423). Cell death is reported as a percentage of Annexin-V positive or caspase 3/7-positive
of total events. Survival is plotted as the percentage of CD19+, proliferating B cells normalized by
input volume using the FACS Canto II high-throughput 96-well sampler to DMSO-treated control
cells.
Protein stability
Protein stability was assayed by incubating LCLs in 15 mM cycloheximide (Sigma, C1988). Time
points were taken immediately before addition (0 min), and then at 30, 60, and 120 min after addi-
tion of cycloheximide and analyzed by western blot loading 10 mg of protein per lane.
Mitochondrial isolation
Mitochondria isolation was performed using a mitochondria isolation kit (Thermo Scientific) on 50
million cells. Cells were lysed with Reagents A, B, and C as supplied by the manufacturer’s kit. Mito-
chondrial pellets were lysed in 0.1% Triton lysis buffer with protease and phosphatase inhibitors.
Total, cytoplasmic, and mitochondrial fractions were measured by Bradford assay and 5 mg protein
was loaded per lane.
Nascent transcription profiling
The ability to capture nascently transcribed RNA was modified from previously described work
(Payne et al., 2014). In brief, cells were treated with 200 mM 4-thiouridine (4sU) for one hour before
total RNA was harvested in 1 mL of TRIzol (Life Technologies). Nascently transcribed RNA over this
time period incorporated 4sU, which was subsequently biotinylated and pulled down using streptavi-
din MyOne C1 Dynabeads (Invitrogen). RNA was reverse transcribed and qPCR was performed as
described above.
Chromatin immunoprecipitation
Chromatin Immunoprecipitation (ChIP) was performed as described previously (Bazot et al., 2015)
using a Millipore ChIP assay kit (17-295) and sonicated with a standard Diagenode Bioruptor sonica-
tor. All antibodies used can be found in the Supplementary file 1.
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Chromatin conformation capture
Chromatin Conformation Capture (CCC) was performed as described previously (Hage`ge et al.,
2007). In brief, chromatin was crosslinked with formaldehyde and isolated from LCLs, whereupon it
was digested overnight with the restriction enzyme HindIII. Digested chromatin was then diluted and
ligated overnight. Reversal of crosslinks, proteinase K digestion, and phenol-chloroform extraction
yielded DNA circles that were assayed by TaqMan qPCR. All oligos and probes used can be found
in the Supplementary file 1.
Transfection of LCLs
pCEP-EBNA3A, an episomal expression vector, was introduced into LCLs using the MicroPorator
MP-100 (Digital Bio). Cells were incubated with DNA and shocked at 1300V for 1 pulse of 30 ms and
then recovered in 15% FBS containing RPMI. Cells were co-transfected with an additional pCEP-
TdTomato plasmid to mark transfected cells with red fluorescence.
Statistical analysis
Student’s 2-way ANOVA and two-tailed t-test were calculated using GraphPad Prism 5.0 software.
*p<0.05, **p<0.01, and ***p<0.001 were considered significant. IC50 values were calculated by non-
linear regression using GraphPad and 95% confidence intervals were reported.
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